1. Adjuvant Trastuzumab for Breast Cancer

   • Tallal Younis
   • Chris Skedgel

   Commentary 23 December 2012 Pages: 361 - 365

   

2. Health Economic and Infectious Disease Modelling

   • Andrea Anonychuk
   • Murray Krahn

   Commentary 23 December 2012 Pages: 367 - 369

3. Modelling the Epidemiology of Infectious Diseases for Decision Analysis

   • Mark Jit
   • Marc Brisson

   Practical Application 23 December 2012 Pages: 371 - 386

   

4. Cost Effectiveness of Treatments for Inflammatory Bowel Disease

   • Keith Bodger

   Review Article 23 December 2012 Pages: 387 - 401

   

5. Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease

   • Nicole Mittmann
   • Paul Hernandez
   • Tobias Welte

   Original Research Article 23 December 2012 Pages: 403 - 414

   

6. Erratum to: Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease

   • Nicole Mittmann
   • Paul Hernandez
   • Tobias Welte

   Erratum 23 December 2012 Pages: 414 - 414

7. Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer

   • Peter S. Hall
   • Claire Hulme
   • David A. Cameron

   Original Research Article 23 December 2012 Pages: 415 - 432

   

8. Is There a Role for Pharmacoeconomics in Developing Countries?

   • Román Pérez Velasco
   • Yot Teerawattananon

   Correspondence 23 December 2012 Pages: 433 - 435

9. Is There a Role for Pharmacoeconomics in Developing Countries?

   • Jonathan R. Harper

   Correspondence 23 December 2012 Pages: 435 - 436

10. The Authors’ Reply

    • Zaheer-Ud-Din Babar
    • Shane L. Scahill

    Correspondence 23 December 2012 Pages: 436 - 437

11. Rotavirus Vaccine RIX4414 (Rotarix™)

    • Greg L. Plosker

    Adis Pharmacoeconomic Drug Evaluation 23 December 2012 Pages: 439 - 454